Open Demo Account
Home / Market Update / J&J’s Coronavirus Vaccine Adds More Than $500 Million to Third-Quarter Sales

J&J’s Coronavirus Vaccine Adds More Than $500 Million to Third-Quarter Sales

Adel 19 October, 2021 4:12 pm Market Update

Johnson & Johnson said it sold $502 million of its coronavirus vaccine in the third quarter, in its third-quarter financial statements that beat Wall Street earnings expectations.

The company reported adjusted earnings per share of $2.60 per share, versus expectations of $2.35 per share.

The company’s revenue came to $23.34 billion, versus expectations of $23.72 billion.

J&J raised its full-year earnings forecast to between $9.77 per share and $9.82 per share, from its previous estimate of $9.60 to $9.70 per share.

The company expects sales to range from $94.1 billion to $94.6 billion, up from a previous forecast of $93.8 billion to $94.6 billion.

Tags

Check Also

Could USDT Removal Impact EU Amid Crypto Boom Promised By Trump?

The European Union’s Markets in Crypto-Assets (MiCA) regulation, designed to enhance transparency and combat financial …

This site contains information and opinions for the purpose of providing only general information and can not be relied upon. The information and opinions contained in this Site shall in no way constitute an offer or solicitation to buy, sell or subscribe to any investment product. Users of this site shall bear any risks arising from the use of any information, opinion, program, service or material. Noor Trends reserves the right to make any change to the Site, the information, opinions, materials, products, programs, services or prices (if any) at any time without notice.
All copyrights reserved Noor Trends